Efficacy of Biweekly Ranibizumab (0.5 mg) for Exudative Macular Degeneration Retinal Edema Refractory to Anti-VEGF

Inclusion Criteria: * Age \> 50 years * Exudative age related macular degeneration in study eye involving the fovea * Best Corrected Visual Acuity (by ETDRS) letter score in study eye of \< 85 and \> 24 (approximate Snellen equivalent 20/20 to 20/320) * Persistent intraretinal or subretinal fluid on SD OCT despite a minimum of 5 intravitreal anti-VEGF injections administered every 4-6 weeks in the in the 6 months preceding enrollment in the study eye * At least 30 days from last intravitreal anti-VEGF injection in the study eye Exclusion Criteria: * Patient who are receiving systemic anti-VEGF or proangiogenic therapy * Patients on chronic high doses corticosteroid therapy (\> than 10 mg of oral prednisone or equivalent greater than 10 days) * Patients on chronic immunosuppressant therapy * Patients on drugs known to have toxic side effects on the retina e.g. hydroxychloroquine * History of intravitreal corticosteroids in study eye within 4 months of baseline * Uncontrolled hypertension (defined as systolic \>180 mm Hg and/or diastolic \> 100 mm Hg while patient is sitting) * History of stroke or APTC event in the previous year * Any intraocular surgery in study eye within 90 days of baseline * Presence of vitreomacular traction in study eye * Presence of significant epiretinal proliferation in study eye * Evidence of active infection in either eye * Uncontrolled glaucoma in the study eye defined as a pressure \> 25 mmHg on maximal medical therapy